48
Participants
Start Date
December 4, 2018
Primary Completion Date
June 30, 2022
Study Completion Date
September 30, 2022
Eltrombopag
subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50\~150×109/L，the eltrombopag dose Maintain. platelet count between 150\~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences, Tianjin
Collaborators (1)
Novartis
INDUSTRY
Qilu Hospital of Shandong University
OTHER
The Second Affiliated Hospital of Kunming Medical University
OTHER
Tianjin First Central Hospital
OTHER
Tianjin Medical University Second Hospital
OTHER
Henan Cancer Hospital
OTHER_GOV
The Second Hospital of Hebei Medical University
OTHER
North China University of Science and Technology
OTHER
The Affiliated Hospital of Qingdao University
OTHER
The First Affiliated Hospital of University of Science and Technology of China
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER
Institute of Hematology & Blood Diseases Hospital, China
OTHER